ArticleCancer medicine2026
Finite-Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia-A Pilot Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundContinuous venetoclax-azacitidine (VA) therapy is currently the major intervention for elderly or unfit acute myeloid leukemia (AML) patients. However, moderate chemotherapy with finite-duration VA could achieve comparable or superior efficacy to infinite-duration VA. Additionally, umbilical cord blood (UCB) transfusion improves clinical safety for elderly patients. Therefore, this single-center study presents an improved approach: A finite-duration VA and decitabine priming with intermediate-dose cytarabine followed by UCB infusion.
methodsWe included elderly AML patients who underwent the treatment between March 2021 and May 2024. Induction and maintenance regimens were VA. Our consolidation therapy involved intravenous decitabine (20 mg/m
resultsWe analyzed 16 patients with a median follow-up of 53.6 months (95% CI: 36.2-71.0 months), and 7 out of 16 participants were at adverse risk. The median VA cycle number prior to disease relapse was 5 (IQR: 4-6). The median DOR was 17.4 months (95% CI: 7.3-27.5 months), with a 1-year DOR rate of 68.8% and a 2-year DOR rate of 35.2%. The median OS was 24.9 months (95% CI: 9.8-40.1 months), with a 1- and 2-year OS rate of 100% and 55.6%. Specifically, among the 8 patients with IDH1/2 mutations, 4 experienced sustained remission, with 1-year OS of 100%. Hematological and non-hematological toxicities remained manageable during the consolidation phase.
conclusionsWe demonstrated prolonged survival, particularly in patients with IDH mutations, using the modified intervention. This approach holds significant value for elderly patients with untreated AML who are unfit for standard treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.